H. L. Haak

Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?

Martin den Heijer, W.B.J. Gerrits, H. L. Haak et al. · The Lancet · 1995 · 371 citations

Thrombosis, Venous Disease, Venous Thrombosis +7

Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.

Bob Löwenberg, Stefan Suciu, E Archimbaud et al. · Journal of Clinical Oncology · 1998 · 288 citations · Full text

Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.

M Krámer, J. Hermans, Jefferson Parker et al. · Journal of Clinical Oncology · 1996 · 205 citations

Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases

H. Kerkhofs, J. Hermans, H. L. Haak et al. · British Journal of Haematology · 1987 · 193 citations

Prognostic Factors, Mixed-phenotype Acute Leukemia, Prognosis +16

Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases

Henk Schonewille, H. L. Haak, Annette M. van Zijl · Transfusion · 1999 · 167 citations · Full text